Charles Schwab Investment Management Inc. Sells 22,939 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Charles Schwab Investment Management Inc. lowered its position in iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 10.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 199,196 shares of the company’s stock after selling 22,939 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.55% of iTeos Therapeutics worth $1,530,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. SG Americas Securities LLC raised its position in iTeos Therapeutics by 12.2% in the 4th quarter. SG Americas Securities LLC now owns 13,866 shares of the company’s stock worth $106,000 after purchasing an additional 1,508 shares during the period. Point72 DIFC Ltd bought a new position in shares of iTeos Therapeutics during the third quarter valued at approximately $31,000. Empowered Funds LLC raised its holdings in shares of iTeos Therapeutics by 5.0% in the fourth quarter. Empowered Funds LLC now owns 69,072 shares of the company’s stock worth $530,000 after buying an additional 3,305 shares during the period. US Bancorp DE raised its holdings in shares of iTeos Therapeutics by 40.1% in the fourth quarter. US Bancorp DE now owns 16,919 shares of the company’s stock worth $130,000 after buying an additional 4,843 shares during the period. Finally, JPMorgan Chase & Co. lifted its stake in shares of iTeos Therapeutics by 1.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 467,319 shares of the company’s stock worth $4,771,000 after acquiring an additional 5,368 shares during the last quarter. Institutional investors own 97.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on ITOS shares. Wedbush reaffirmed an “outperform” rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a research report on Wednesday, March 5th. JPMorgan Chase & Co. cut their price target on shares of iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating on the stock in a report on Thursday, March 6th. HC Wainwright reaffirmed a “buy” rating and issued a $46.00 price target on shares of iTeos Therapeutics in a research note on Thursday, March 6th. Finally, Wells Fargo & Company lowered their price objective on shares of iTeos Therapeutics from $19.00 to $17.00 and set an “overweight” rating for the company in a research report on Thursday, March 6th.

iTeos Therapeutics Stock Down 5.7 %

Shares of NASDAQ ITOS opened at $6.32 on Friday. iTeos Therapeutics, Inc. has a twelve month low of $6.30 and a twelve month high of $18.75. The firm has a market cap of $241.39 million, a PE ratio of -2.01 and a beta of 1.38. The business has a fifty day simple moving average of $7.27 and a two-hundred day simple moving average of $8.40.

iTeos Therapeutics (NASDAQ:ITOS) last released its quarterly earnings data on Wednesday, March 5th. The company reported ($1.01) earnings per share for the quarter, beating the consensus estimate of ($1.14) by $0.13. On average, research analysts expect that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current year.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.